Protective Effects of IL-6 Blockade in Sepsis Are Linked to Reduced C5a Receptor Expression
Top Cited Papers
Open Access
- 1 January 2003
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 170 (1) , 503-507
- https://doi.org/10.4049/jimmunol.170.1.503
Abstract
IL-6 is known to be an important pro- and anti-inflammatory cytokine, which is up-regulated during sepsis. Our previous work has suggested a role for IL-6 in the up-regulation of C5aR in sepsis. We reported earlier that interception of C5a or C5aR results in improved outcomes in experimental sepsis. Using the cecal ligation/puncture (CLP) model in mice, we now demonstrate that treatment with anti-IL-6 Ab (anti-IL-6) results in significantly improved survival, dependent on the amount of Ab infused. CLP animals showed significantly increased binding of 125I-labeled anti-C5aR to organs when compared to either control mice at 0 h or CLP animals infused with normal rabbit 125I-labeled IgG. Binding of 125I-labeled anti-C5aR to lung, liver, kidney, and heart was significantly decreased in anti-IL-6-treated animals 6 h after CLP. RT-PCR experiments with mRNA isolated from various organs obtained 3, 6, and 12 h after CLP demonstrated increased C5aR mRNA expression during the onset of sepsis, which was greatly suppressed in CLP mice treated with anti-IL-6. These data suggest that IL-6 plays an important role in the increased expression of C5aR in lung, liver, kidney, and heart during the development of sepsis in mice and that interception of IL-6 leads to reduced expression of C5aR and improved survival.Keywords
This publication has 41 references indexed in Scilit:
- C5a receptor and thymocyte apoptosis in sepsisThe FASEB Journal, 2002
- Protective effects of anti‐C5a peptide antibodies in experimental sepsisThe FASEB Journal, 2001
- Anti-interleukin-6 antibody treatment improves survival during gut-derived sepsis in a time-dependent manner by enhancing host defenseCritical Care Medicine, 1995
- Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees.The Journal of Experimental Medicine, 1994
- Impaired immune and acute-phase responses in interleukin-6-deficient miceNature, 1994
- Limited involvement of interleukin‐6 in the pathogenesis of lethal septic shock as revealed by the effect of monoclonal antibodies against interleukin‐6 or its receptor in various murine modelsEuropean Journal of Immunology, 1992
- Protective effect of anti‐interleukin (IL)‐6 antibody against endotoxin, associated with paradoxically increased IL‐6 levelsEuropean Journal of Immunology, 1992
- Molecular cloning and expression of an IL-6 signal transducer, gp130Cell, 1990
- Dose-dependent increase in plasma interleukin-6 after recombinant tumour necrosis factor infusion in humansClinical and Experimental Immunology, 1990
- Endotoxin, tumor necrosis factor-α and interleukin 1 induce interleukin 6 production in vivoClinical Immunology and Immunopathology, 1989